Therapy Directory

Cisplatin clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Cisplatin as a study intervention. Browse Cisplatin recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 1:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

362

Shown on this page

Current sort

Stored official records

Open in full search

Conditions: Non-Small Cell Lung Cancer
Interventions: Carboplatin, Cisplatin, Durvalumab, Gemcitabine, Paclitaxel, Pemetrexed, Placebo, Surgery; Drug · Other · Procedure
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 825 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 31
States / cities: Phoenix, Arizona • Duarte, California • Orange, California + 25 more

Conditions: HPV-Negative Squamous Cell Carcinoma
Interventions: Carboplatin, Cetuximab, Cisplatin, Low Dose Radiation, Paclitaxel, Standard Dose Radiation, TFHX Regimen; Drug · Radiation
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Metastatic Urothelial Carcinoma, Muscle-Invasive Bladder Carcinoma
Interventions: Cisplatin, Enfortumab vedotin, Gemcitabine, Pembrolizumab, SEphB4-HSA; Drug
Lead sponsor: Vasgene Therapeutics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Biomarkers, Biomarkers / Blood, Immunotherapy, Large Cell Neuroendocrine (NE) Tumors, Small Cell Lung Cancer, Treatment Failure
Interventions: Carboplatin/Cisplatin -Etoposide - Atezolizumab; Drug
Lead sponsor: Oncology Center of Biochemical Education And Research; Other
Eligibility: 18 Years to 85 Years
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Urothelial Carcinoma of the Urinary Bladder
Interventions: Cabazitaxel, Cisplatin, Gemcitabine; Drug
Lead sponsor: Guarionex J. Decastro; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer
Interventions: Cisplatin, Postoperative radiotherapy; Drug · Radiation
Lead sponsor: Lisette Nixon; Government
Eligibility: 18 Years and older
Enrollment: 1,269 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2028
U.S. locations: 3
States / cities: Redwood City, California • Orlando, Florida • Houston, Texas

Conditions: Non-Small Cell Lung Cancer
Interventions: Alectinib, Carboplatin, Cisplatin, Datopotamab deruxtecan, Durvalumab, Etoposide, Gefitinib, Necitumumab, Osimertinib, Pemetrexed, Savolitinib, Selpercatinib, Selumetinib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 16
States / cities: Duarte, California • Los Angeles, California • Sacramento, California + 11 more

Conditions: Lung Cancer
Interventions: Afatinib, Cisplatin, Pemetrexed, Radiation, Surgery; Drug · Radiation · Procedure
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2024
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Epithelial Ovarian Cancer, Fallopian Tube Cancer, Fallopian Tube Carcinoma, Ovarian Carcinoma, Primary Peritoneal Carcinoma, Stage III Ovarian Cancer, Stage IV Ovarian Cancer
Interventions: Adjuvant Chemotherapy, Carboplatin, Cisplatin, Cytoreductive Surgery (CRS), Hyperthermic intraperitoneal chemotherapy, Paclitaxel, Questionnaire; Drug · Procedure · Other
Lead sponsor: Mercy Medical Center; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Carcinoma, Small Cell Lung
Interventions: Cisplatin/carboplatin plus etoposide, RRx-001 + eLOOP Device; Drug
Lead sponsor: EpicentRx, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Tampa, Florida • Westwood, Kansas

Conditions: Cancer of the Head and Neck, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Oropharynx Cancer, Throat Carcinoma
Interventions: Cisplatin injection; Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Chemotherapy, Adjuvant, Gastric Cancer, Minimally Invasive Surgical Procedures, Peritoneal Metastases
Interventions: Cisplatin, Doxorubicin; Drug
Lead sponsor: Odense University Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Duarte, California

About this Cisplatin clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Cisplatin as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results: Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Cisplatin.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Cisplatin clinical trials

Filter and sort this therapy

Stored official records

A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer

Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer

Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors

Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS)

Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder

Post-operative Adjuvant Treatment for HPV-positive Tumours (PATHOS)

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

Afatinib With CT and RT for EGFR-Mutant NSCLC

HOT: HIPEC in Ovarian Cancer as Initial Treatment

A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer

Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer

The Efficacy of PIPAC and Minimally Invasive Radical Resection in High-risk Gastric Cancer Patients.

About this Cisplatin clinical trials directory page